{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:12:09Z","timestamp":1790871129234,"version":"4.1.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2019,5,4]]},"DOI":"10.1080\/03007995.2018.1532885","type":"journal-article","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T20:01:46Z","timestamp":1538769706000},"page":"829-835","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom"],"prefix":"10.1080","volume":"35","author":[{"given":"Ming-Hui","family":"Tai","sequence":"first","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Macclesfield, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Bailey","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Macclesfield, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Williams","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Macclesfield, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Hatz","sequence":"additional","affiliation":[{"name":"Amgen GmbH, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Campos Tapias","sequence":"additional","affiliation":[{"name":"Amgen SA, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Catterick","sequence":"additional","affiliation":[{"name":"Amgen UK, Uxbridge, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Worth","sequence":"additional","affiliation":[{"name":"Amgen (Europe) GmbH, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"CIT0001","volume-title":"European cardiovascular disease statistics","author":"Wilkins E","year":"2017"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.09.004"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2016.05.037","volume":"252","author":"Task Force Members","year":"2016","journal-title":"Atherosclerosis"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"CIT0008","unstructured":"REPATHA\u00ae (evolocumab) prescribing information. Thousand Oaks, CA: Amgen Inc; 2016"},{"key":"CIT0009","unstructured":"PRALUENT\u00ae (alirocumab) prescribing information. Bridgewater, NJ: Sanofi-Aventis; 2017"},{"key":"CIT0010","author":"Rane PB","journal-title":"Am J Cardiovasc Drugs"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802457040"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352"},{"key":"CIT0013","author":"Sanidad MD","year":"2016","journal-title":"Informe de posicionamiento terap\u00e9utico de evolocumab (Repatha\u00ae) en hipercolesterolemia"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.jncimonographs.a003460"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.12.015"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12439"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.11.027"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.04.014"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.004652"},{"key":"CIT0021","unstructured":"World Health Organization. Body mass index classification. World Health Organization, 2018. Available at: http:\/\/apps.who.int\/bmi\/index.jsp?introPage=intro_3.html [Last accessed April 11, 2018]"},{"key":"CIT0022","doi-asserted-by":"crossref","unstructured":"Ray K, Bruckert E, Annemans L, et al. Characteristics of patients prescribed Evolocumab in Europe. Does clinical use match clinical guidelines? European Heart Journal 2018;39(supp 1):ehy565.P1699","DOI":"10.1093\/eurheartj\/ehy565.P1699"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2018.1532885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T20:04:26Z","timestamp":1599422666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2018.1532885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,4]]}},"alternative-id":["10.1080\/03007995.2018.1532885"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2018.1532885","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}